Proven across different API types, from peptides and biologics to small molecules. Our SynBiosys® based microsphere platform fully supports the development of competitive, patient-friendly long-acting drug products across a wide range of therapeutic applications.
Monodispersed microspheres; full control over particle size with smooth injectability requiring small needle sizes
Unique SynBiosys® polymer platform using biodegradable and proven safe polymers
Burst control
Suitable for a variety of API classes, including proteins, peptides and small molecules
Full control over release profile by diffusion, zero or first order kinetics
High encapsulation efficiency (> 85%)
High loadings (up to 50%)
Early phase development, upscaling and manufacturing in house
Strong IP position
Injectable, biodegradable microspheres are one of the most effective and versatile systems for parenteral drug delivery, offering the ability to deliver therapeutic agents in a controlled and sustained manner over extended periods.
Microspheres are formulated using our safe SynBiosys® bioresorbable polymers which release the active pharmaceutical ingredient (API) at a predictable rate by diffusion. This approach can maintain therapeutic drug levels for weeks or even months after a single injection, reducing dosing frequency, improving patient compliance, and optimizing treatment outcomes.
At InnoCore, our expertise in developing bespoke microsphere formulations has been developed both in-house and through strong technology partnerships. We specialise in the design and production of high-quality injectable microsphere formulations, producing monodisperse microspheres with a controlled particle size, typically between 20–50 microns. Our aim is to ensure optimal reproducibility, injectability, predictable drug release, and minimal injection site discomfort.
These precisely engineered microspheres are suitable for sustained release of a wide variety of pharmaceutical compounds, including anti-infectives, hormones, proteins, antibodies, and peptides.
Our proven track record spans the successful manufacture of monodisperse spherical microparticles for both small molecules, peptides and complex biologics, with each formulation tailored to the drug’s specific stability and desired sustained release and therapeutic profile. This adaptability makes our microsphere technology a platform solution for multiple therapeutic areas, including oncology, endocrinology, infectious diseases, and reproductive health.
Looking toward the future, InnoCore is committed to advancing the microsphere technology in conjunction with our SynBiosys® drug delivery platform to create the next generation of LAI products with enhanced performance and patient benefits.
Unique benefits of the InnoCore microsphere platform include:
We combine our scientific excellence with state-of-the-art technology and a collaborative approach.
We deliver microsphere-based solutions that meet the evolving needs of drug developers, offering our partners a reliable, scalable, and patient-focused platform for sustained drug delivery.
"*" indicates required fields